VIM and non-small cell lung carcinoma: In addition to acting as a blocker of the PTBP1-mediated switch of PKM1 to PKM2, circEPB41L2 also acts as an inhibitor of PTBP1-stimulated Vimentin activation and E-cadherin inactivation to limit NSCLC development and metastasis.